Breslin et al. (2017) developed neratinib-resistant Her2-positive breast cancer cells and confirmed their bi-directional cross-resistance to the Her2-targeting drugs trastuzumab, lapatinib and afatinib. This evidence concerns the gene ERBB2 and breast cancer.